Post-marketing safety of elacestrant in breast cancer: a pharmacovigilance investigation using the FDA adverse event reporting system
FAERS data analyses were conducted to evaluate the safety of post-marketing clinical use of elacestrant and to ensure that physicians identify the risk factors for the AEs of this drug.
Authors
- Ziyi Fan (ORCID: https://orcid.org/0009-0004-7014-9705)
- Shuang Guo (ORCID: https://orcid.org/0000-0002-5636-5506)
- Bin Song (ORCID: https://orcid.org/0000-0002-7269-2101)
- Yanan Xu (ORCID: https://orcid.org/0009-0007-8299-1344)
Institutions
- Shanxi Medical University (CN)
- Second Hospital of Shanxi Medical University (CN)
- Shanxi Academy of Medical Sciences (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1186/s40360-025-00887-2
- Citations
- 1
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 1.16